As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots in Cambridge. That said, the company won’t be moving far from its ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has reaffirmed its positive opinion by consensus for ...

Biogen signed a 585K SF lease at the 75 Broadway St. development in Cambridge, the company announced Monday morning. It plans to move to the building in 2028 as its global headquarters.

With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

Biogen signs lease for Kendall Common as part of multi-year real estate optimization plan to modernize its facilities and consolidate its Massachusetts real estate footprint New building will be ...

MESA, Ariz. — The Chicago Cubs spring training facility will soon be undergoing a few upgrades. The city of Mesa approved $16 million in funding for improvements at Sloan Park during a Feb. 24 ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...